Phase 3 Readout~month

Phase 3 Topline: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficac

Drug
sickle
Indication
Sickle Cell Disease

Other upcoming events for AGIO

Phase 3 ReadoutPhase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy a
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy a
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficac — AGIO Phase 3 Readout | BioSniper